Evidence map›Paper›PMID 39340691›Full record

Trial reportInflammopharmacology2024

Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study.

Mohannad O Khrieba, Sahar K Hegazy, Wessam Mustafa, Sahar M El-Haggar

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05962957 (Clinical Study to Compare the Possible Safety and Efficacy of Pentoxifylline and Celecoxib in Patients With Parkinson's Disease Treated With Conventional Treatment), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05962957 phase2completednot on this map

Clinical Study to Compare the Possible Safety and Efficacy of Pentoxifylline and Celecoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

TypeinterventionalSponsorMostafa BahaaRan2023 to 2024Enrolled80ConditionsParkinson DiseaseArmscarbidopa-levodopa, Pentoxifylline 400 MG, Celecoxib 200mg
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. IntravenousJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohannad O KhriebaPharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt. mkhrieba@horus.edu.eg.ORCID http://orcid.org/0000-0003-0489-1579
Sahar K HegazyClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.
Wessam MustafaNeurology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Sahar M El-HaggarClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical presentations of Parkinson's disease (PD), a chronic neurodegenerative condition, include bradykinesia, hypokinesia, stiffness, resting tremor, and postural instability. Recently, neuroinflammation is involved in pathogenesis of PD. Application of nonsteroidal anti-inflammatory drugs captured attention to treat these neuroinflammation.

aimTo investigate the possible effectiveness of celecoxib in patients with PD treated with conventional treatment.

methodsSixty outpatients who fulfilled the inclusion requirements for PD were enrolled in this randomized, prospective, and controlled study. The patients were allocated into two groups at random (n = 30); the control group received standard PD treatment, consisting of levodopa/carbidopa, and the celecoxib group received standard PD treatment plus celecoxib. A neurologist evaluated each patient at the beginning of the treatment and after 6 months. Assessment of Unified Parkinson's disease rating scale (UPDRS) for each patient. Before and after treatment, α -synuclein (α-Syn), tumor necrosis factor alpha (TNF-α), Toll like receptors-4 (TLR-4), nuclear factor erythroid 2-related factor 2 (Nrf-2) and brain-derived neurotropic factor (BDNF) were assessed. Paired and unpaired t tests were used to assess statistical significance within and between groups respectively.

resultsThe celecoxib group exhibited a significant and statistical reduction in the level of measured parameters by unpaired t test as followed: TLR-4 (p = 0.004), TNF-α (p = 0.042), and α-Syn (p = 0.004) apart from a significant increase in BDNF (p = 0.0005) and Nrf-2 (p = 0.004), in comparison with the control group. Also, UPDRS was significantly decreased in celecoxib group (p < 0.05).

conclusionCelecoxib could be a promising adjuvant therapy in managing patients with PD. TRIAL REGISTRATION NUMBER: NCT05962957.

Indexed as

CelecoxibDrug RepositioningParkinson DiseaseAgedalpha-SynucleinAnti-Inflammatory Agents, Non-SteroidalAntiparkinson AgentsBrain-Derived Neurotrophic FactorCarbidopaDrug CombinationsFemaleHumansLevodopaMaleMiddle AgedPilot Projectsalpha-SynucleinAnti-Inflammatory Agents, Non-SteroidalAntiparkinson AgentsBrain-Derived Neurotrophic FactorCarbidopacarbidopa, levodopa drug combinationCelecoxibDrug CombinationsLevodopaToll-Like Receptor 4Tumor Necrosis Factor-alphaBDNFCelecoxibNeuroinflammationParkinson’sα-Synuclein

Identifiers

PMID39340691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.